Former Co-Chief Executive Officer · Lineage Cell Therapeutics, Inc. (LCTX)

Aditya Mohanty

A named executive officer of Lineage Cell Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,323,027

Salary $378,869Stock awards $230,797Bonus $200,000

FY2017: $1,866,390

3rd of 5 named executive officers at Lineage Cell Therapeutics by FY2018 total.

5 named officers on file for Lineage Cell Therapeutics, FY2018

Aditya Mohanty’s pay file — $29

  • 2 fiscal years of pay, line by line
  • LCTX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lineage Cell Therapeutics’s whole pay program stands against its peers

  • Lineage Cell Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LCTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 14, 2019 (DEF 14A).

Free

Get Aditya Mohanty’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Aditya Mohanty compensation by year

Lineage Cell Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Lineage Cell Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$511,423$378,869
Bonus$206,000$200,000
Stock awards$0$230,797
Option awards$1,135,467$278,063
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$13,500$235,298
Total$1,866,390$1,323,027

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lineage Cell Therapeutics, Inc. DEF 14A filed June 14, 2019, accession 0001493152-19-009214, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lineage Cell Therapeutics, Inc. filed document, accession 0001493152-19-009214. Every figure is read from that document and cited to the page and table it appears in. Filed June 14, 2019.

$1.9M
$1.3M
FY17
FY18
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU34,765$31,636—
Option247,199—$2.05
Option435,169—$2.56
Option154,494—$2.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Lineage Cell Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Lineage Cell Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Brian CulleyChief Executive Officer$2,772,378
Michael WestFormer Co-Chief Executive Officer$1,365,113
Aditya Mohanty · this pageFormer Co-Chief Executive Officer$1,323,027
Russell SkibstedFormer Chief Financial Officer$752,237
Stephana PattonFormer General Counsel$668,049

The full Lineage Cell Therapeutics compensation record

free company brief

This page is one person within Lineage Cell Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Lineage Cell Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lineage Cell Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Aditya Mohanty's compensation dossier · One-time report. No refunds.